• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IBX 16.7% 1.0¢

IMAGION BIOSYSTEMS LIMITED - Corporate Spotlight

We are a multidisciplinary team with expertise in the physics of magnetic fields and... We are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology & the medical application of these fields. Our focus is in the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases.More

Corporate Spotlight

We are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology & the medical application of these fields. Our focus is in the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases.
View the full Corporate Spotlight arrow Created with Sketch.

IBX director resigns, to raise over $2M

VIDEOS

arrow-down-2 Created with Sketch.


The Market Herald Bulletin: Imagion Biosystems (ASX:IBX) director resigns, to raise over $2M - 26th March 2020


The Market Herald: Investment Opportunity in Medical Imaging - Special Report March


Video Interview with Robert Proulx, CEO Imagion Biosystems - March




INVESTMENT OPPORTUNITY MEDICAL IMAGING

arrow-down-2 Created with Sketch.



Read The Article on The Market Herald Here


Medical imaging is revolutionising the way we think about health. Ever-evolving technology continues to agitate key players in the space, pushing them to deliver new tests that detect problems faster and more accurately than ever before.

But if this is such a crucial field, why haven't we heard more about it?


Currently, there's pain in the pricing. Medical imaging equipment can be expensive for hospitals to install and maintain. Moreover, radiology exams may not be covered by health insurance policies or subsidised by the government — leaving patients out of pocket or unable to afford crucial testing.


On top of that, current imaging technology isn't always diagnostic; it may not be able to tell if a cancer is malignant or benign and is often invasive, or even painful.


So as healthcare expenditure continues to rise, radiologists face a challenge. They'll need to work with technology to create cost-effective, efficient and less invasive medical imaging strategies.


In doing so, companies can ensure life-saving testing is more widely accessible. But even more importantly, the growing efficacy of imaging technology will change the way we detect and treat diseases like cancer and arthritis.

Consequently, there's great value to be had in the medical imaging space — and some of our ASX-listed biotechs are more than ready to shake up the field.


An Emerging Technology

Over the last few decades, there's been something of a space race in the medical imaging industry. Companies compete to be the best and brightest in radiology, trying to develop the fastest machine with the highest imaging technology. But nowadays, the bar is even higher.


Karim Boussebaa, senior vice president of Computed Tomography (CT) and Advanced Molecular Imaging (AMI) for Philips, says there's an emphasis on uncovering advanced imaging strategies.


"Not only are we interested in diagnosing the right disease in our patient but it's also important that we do it in the most effective and the most efficient way," Karim explained.


Experts say another catalyst to this competition is rising healthcare costs. In the U.S. alone, health-related expenditure accounted for between six and 15 per cent of the Gross National Product (GNP) in 2012. Moreover, between three and five per cent of this was spent on medical imaging.


"As people are looking to purchase new pieces of equipment it is no longer just about the latest and greatest, but it is going to be more focused," said Samir Patel, a program director to Radiology, Inc.


The market for medical imaging has also expanded in the last half-century – where there used to be three of four big names in the field, there are now many more looking for a slice in the pie. As a result, fresh faces have brought new standards and are pushing companies to innovate like never before.


The Key Imaging Players

Fortunately, many homegrown biotech companies are actively exploring the medical imaging space. 

In fact, there are seven ASX-listed players working in the imaging technology field, such as Imagion Biosystems (ASX:IBX), Resonance Health (ASX:RHT) and Compumedics (ASX:CMP). Meanwhile, names like Uscom (ASX:UCM) and Impedimed (ASX:IPD) are developing monitoring and medical devices.


While each of these companies have different targets, they all have some involvement in administering or developing technology to carry out diagnostic imaging, ultrasounds, CT or PET scans and radiology services.


READ THE ARTICLE HERE ON THE MARKET HERALD 



THE 6TH WAY OF MEDICAL IMAGING

arrow-down-2 Created with Sketch.


OUR TECHNOLOGY IS THE 6TH WAY OF MEDICAL IMAGING


The X-ray, ultrasound, CT scanning, MRI, and PET make up the five imaging techniques used in clinical practice. Imagion Biosystems’ unique technology has the breakthrough potential to be the sixth.


In these videos, Imagion Biosystems Non-Executive Director Mike Harsh presents to investors on the history of medical imaging and explains the unique properties of our MagSense technology that give it groundbreaking status as a potential sixth imaging method.




IMAGION PODCAST EPISODES

arrow-down-2 Created with Sketch.


Imagion Podcast Episode 1: Scientific Advisory Board Member John Hazle and WE Communications Taryn Silver

In the first episode of the Imagion Biosystems podcast series, Board member Dr John Hazle speaks on his background, the imaging sector and how he came to join Imagion.


Dr. Hazle is a medical physicist with over 25 years of experience. He is board-certified and licensed in Texas for both therapeutic and diagnostic medical physics. His research interests include image-guided therapy, pre-clinical imaging, and novel early detection technologies.



Imagion Podcast Episode 2: Director Mike Harsh speaks with Marisa Zammit from WE Communications

In this episode, host Marisa asks Mike about his background, how Mike came to join Imagion and how Mike thinks Imagion’s technology could transform the imaging industry.


Mike Harsh is a Non-Executive Director of Imagion. Mike has over 36 years of experience in healthcare technology, focused on diagnostic imaging having served as Vice President and Chief Technology Officer for GE Healthcare.






ABOUT

arrow-down-2 Created with Sketch.

Our Mission


Imagion Biosystems is dedicated to providing tools to find and eliminate cancer. We are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology and the medical application of these fields. Our focus is in the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases. Our technologies also hold the promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention.


Our proprietary technologies and methods employ magnetic nanoparticles targeted towards cells associated with cancer and other diseases and provide the ability to detect these cells using highly sensitive magnetic sensors. These methods have numerous preclinical and clinical applications. Preclinical research projects have focused on the early detection of breast cancer, ovarian cancer, and prostate cancer.


The Technology


PrecisionMRX Nanoparticles

PrecisionMRX nanoparticles are extensively characterized superparamagnetic nanoparticles manufactured by Imagion Biosystems. The PrecisionMRX nanoparticles are composed of a 25 nm iron oxide core and specialized polymer coating. The nanoparticles can be functionalized to delay clearance from blood circulation and enable targeted attachment to tumor cells. Due to stringent manufacturing control over nanoparticle size, PrecisionMRX nanoparticles can be used in a variety of applications in addition to superparamagnetic relaxometry, including magnetic resonance imaging, magnetic particle imaging, magnetically induced hyperthermia, magnetomotive ultrasound imaging, and magnetically based immunoassays and cell enrichment assays.

Superparamagnetic Relaxometry

Superparamagnetic relaxometry combines the use of sensitive magnetic sensors and the superparamagnetic properties of iron oxide (Fe3O4) nanoparticles. The unique properties of the nanoparticles combined with tumor-targeting biomarkers allows specific attachment to cancer cells. Nanoparticles behave differently when bound to a cell by the antibody vs. remaining free in circulation. The different magnetic fields produced results in high detection specificity between attached and unattached nanoparticles. In the detection of cancer cells, superparamagnetic relaxometry has been shown to be several orders of magnitude more sensitive than conventional imaging methods.


(20min delay)
Last
1.0¢
Change
-0.002(16.7%)
Mkt cap ! $5.112M
Open High Low Value Volume
1.2¢ 1.2¢ 1.0¢ $16.40K 1.509M

Buyers (Bids)

No. Vol. Price($)
1 26130 1.1¢
 

Sellers (Offers)

Price($) Vol. No.
1.2¢ 3684123 7
View Market Depth
Last trade - 15.09pm 07/04/2020 (20 minute delay) ?
(live)
Last
1.1¢
  Change
-0.002 ( 8.33 %)
Open High Low Volume
1.0¢ 1.1¢ 1.0¢ 609232
Last updated 15.51pm 07/04/2020 (live) ?
IBX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.